Document is current
Any future updates will be listed below
-
Authors
Hebbar, Nikhil
Epperly, Rebecca https://orcid.org/0000-0002-8998-0732
Vaidya, Abishek https://orcid.org/0000-0001-8458-7950
Thanekar, Unmesha
Moore, Sarah E. https://orcid.org/0000-0003-3925-8538
Umeda, Masayuki
Ma, Jing
Patil, Sagar L. https://orcid.org/0000-0003-2583-2092
Langfitt, Deanna https://orcid.org/0000-0003-0941-5360
Huang, Sujuan
Cheng, Cheng
Klco, Jeffery M. https://orcid.org/0000-0003-2961-6960
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
Velasquez, M. Paulina https://orcid.org/0000-0002-1533-7234
-
Funding
Funding for this research was provided by:
Assisi Foundation of Memphis
American Lebanese Syrian Associated Charities
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA021765, P01CA096832, R50CA211481)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 31 May 2021
Accepted: 12 January 2022
First Online: 31 January 2022
Competing interests
: N.H., R.E., A.V., S.G., and M.P.V. have patent applications in the field of immunotherapy (WO2021216994 - GRP78 targeted adoptive cell therapy). S.G. has a research collaboration with TESSA Therapeutics, is a DSMB member of Immatics, and on the scientific advisory board of Tidal. The remaining authors declare no competing interests.
